[go: up one dir, main page]

DK164592C - Thyroninanaloge forbindelser, fremgangsmaader til fremstilling af disse samt farmaceutiske praeparater indeholdende dem - Google Patents

Thyroninanaloge forbindelser, fremgangsmaader til fremstilling af disse samt farmaceutiske praeparater indeholdende dem

Info

Publication number
DK164592C
DK164592C DK018586A DK18586A DK164592C DK 164592 C DK164592 C DK 164592C DK 018586 A DK018586 A DK 018586A DK 18586 A DK18586 A DK 18586A DK 164592 C DK164592 C DK 164592C
Authority
DK
Denmark
Prior art keywords
hydrogen
4alkyl
thyronin
procedures
preparing
Prior art date
Application number
DK018586A
Other languages
Danish (da)
English (en)
Other versions
DK164592B (da
DK18586A (da
DK18586D0 (da
Inventor
Paul David Leeson
John Colin Emmett
Anthony Hubert Underwood
David Ellis
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of DK18586D0 publication Critical patent/DK18586D0/da
Publication of DK18586A publication Critical patent/DK18586A/da
Publication of DK164592B publication Critical patent/DK164592B/da
Application granted granted Critical
Publication of DK164592C publication Critical patent/DK164592C/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/673Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by change of size of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/12Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
DK018586A 1985-01-18 1986-01-15 Thyroninanaloge forbindelser, fremgangsmaader til fremstilling af disse samt farmaceutiske praeparater indeholdende dem DK164592C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8501372 1985-01-18
GB858501372A GB8501372D0 (en) 1985-01-18 1985-01-18 Chemical compounds

Publications (4)

Publication Number Publication Date
DK18586D0 DK18586D0 (da) 1986-01-15
DK18586A DK18586A (da) 1986-07-19
DK164592B DK164592B (da) 1992-07-20
DK164592C true DK164592C (da) 1992-12-07

Family

ID=10573093

Family Applications (1)

Application Number Title Priority Date Filing Date
DK018586A DK164592C (da) 1985-01-18 1986-01-15 Thyroninanaloge forbindelser, fremgangsmaader til fremstilling af disse samt farmaceutiske praeparater indeholdende dem

Country Status (24)

Country Link
US (3) US4766121A (es)
EP (1) EP0188351B1 (es)
JP (1) JPH07103070B2 (es)
KR (1) KR930011302B1 (es)
CN (1) CN1010310B (es)
AT (1) ATE61581T1 (es)
AU (1) AU577917B2 (es)
CA (1) CA1319148C (es)
DE (1) DE3678000D1 (es)
DK (1) DK164592C (es)
ES (1) ES8800157A1 (es)
FI (1) FI860229A7 (es)
GB (1) GB8501372D0 (es)
GR (1) GR860122B (es)
HU (1) HU194807B (es)
IE (1) IE58867B1 (es)
IL (1) IL77605A (es)
JO (1) JO1439B1 (es)
NO (1) NO860159L (es)
NZ (1) NZ214843A (es)
PH (1) PH22691A (es)
PT (1) PT81844B (es)
ZA (1) ZA86319B (es)
ZW (1) ZW886A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5371284A (en) * 1987-09-03 1994-12-06 Schering Corporation Phenyl acetylenic acetals
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
EP0580550B1 (en) * 1992-07-21 1997-10-22 Novartis AG Oxamic acid derivatives as hypocholesteremic agents
GB9401891D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
AU6277396A (en) * 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
ATE344279T1 (de) 1995-12-13 2006-11-15 Univ California Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
CA2363145C (en) 1999-03-01 2006-02-14 Pfizer Products Inc. Oxamic acids and derivatives as thyroid receptor ligands
EP1033364B1 (en) 1999-03-01 2005-02-23 Pfizer Products Inc. Cyano containing oxamic acids and derivatives as thyroid receptor ligands
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6627660B1 (en) * 1999-11-16 2003-09-30 New River Pharmaceuticals Inc. Stabilized thyroxine compounds
EP1127882A1 (en) * 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
AU2001262113A1 (en) * 2000-03-23 2001-10-03 Bayer Aktiengesellschaft Indoles for treating diseases that can be treated using thyroid hormones
WO2001072692A1 (en) * 2000-03-31 2001-10-04 Pfizer Products Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
US6620830B2 (en) * 2000-04-21 2003-09-16 Pfizer, Inc. Thyroid receptor ligands
DE10024939A1 (de) 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
DE10038007A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Neue Amino-und Amido-Diphenylether für Arzneimittel
DE10046029A1 (de) 2000-09-18 2002-03-28 Bayer Ag Indazole
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
EP1347959A1 (de) 2000-12-27 2003-10-01 Bayer Aktiengesellschaft Indol-derivate
US6777442B2 (en) 2001-03-12 2004-08-17 Bayer Aktiengesellschaft Diphenyl derivatives
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
GB0120691D0 (en) * 2001-08-24 2001-10-17 Karobio Ab Novel Compounds
IL159006A0 (en) * 2001-08-24 2004-05-12 Karobio Ab Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
EP1297833B1 (en) 2001-09-26 2005-12-21 Pfizer Products Inc. Indole carboxylic acids as thyroid receptor ligands
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
AU2006249350B2 (en) 2003-11-19 2012-02-16 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
BRPI0416639A (pt) * 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
EP1819681B1 (en) * 2004-11-23 2009-08-12 Warner-Lambert Company LLC 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
JP4810862B2 (ja) * 2005-04-11 2011-11-09 Jsr株式会社 オニウム塩、それを用いた感放射線性酸発生剤及びポジ型感放射線性樹脂組成物
CA2606498C (en) * 2005-05-26 2016-08-09 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
CN101291640A (zh) * 2005-06-24 2008-10-22 托马斯·拉文 甲状腺素化合物用于人体烧伤和脂肪沉积的治疗
RU2379295C2 (ru) 2005-07-21 2010-01-20 Ф.Хоффманн-Ля Рош Аг Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
EP2066800A2 (en) 2006-08-04 2009-06-10 Decode Genetics EHF Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US8076334B2 (en) 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
CN110198719A (zh) 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
AU2019238090B2 (en) 2018-03-22 2024-08-01 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR289M (fr) * 1959-01-05 1961-02-24 Glaxo Lab Ltd Médicament utilisable dans le traitement de l'hypercholestérolémie et des états apparentés, a base de dérivés de la thyronine.
US3017428A (en) * 1959-08-18 1962-01-16 Univ California Antihypercholesterolemic thyronine derivatives
US3149153A (en) * 1961-12-05 1964-09-15 Smith Kline French Lab 3'-substituted-3, 5-diiodothyronine and salts thereof
DE1200832B (de) * 1961-12-05 1965-09-16 Smith Kline French Lab Verfahren zur Herstellung von 3, 5-Dijodthyroninderivaten
US3287396A (en) * 1963-01-11 1966-11-22 Smith Kline French Lab Phenyldesoxythyronines
GB1047082A (en) * 1963-02-01 1966-11-02 Pfizer & Co C Thyronine derivatives
US3477954A (en) * 1966-06-29 1969-11-11 Armour Pharma Phosphonium iodide complexes of thyroxine,methods of preparing same,and methods of preparing 3,5,3'-l-triiodothyronine therefrom
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds

Also Published As

Publication number Publication date
ZW886A1 (en) 1987-05-13
CN86100894A (zh) 1986-09-03
DK164592B (da) 1992-07-20
US4766121A (en) 1988-08-23
KR930011302B1 (ko) 1993-11-29
NO860159L (no) 1986-07-21
AU5221986A (en) 1986-07-24
JPS61167643A (ja) 1986-07-29
IL77605A0 (en) 1986-07-31
IE860143L (en) 1986-07-18
CN1010310B (zh) 1990-11-07
DK18586A (da) 1986-07-19
GB8501372D0 (en) 1985-02-20
AU577917B2 (en) 1988-10-06
PT81844B (pt) 1988-05-27
DK18586D0 (da) 1986-01-15
ES8800157A1 (es) 1987-11-01
GR860122B (en) 1986-05-19
JPH07103070B2 (ja) 1995-11-08
KR860005788A (ko) 1986-08-13
ATE61581T1 (de) 1991-03-15
EP0188351A3 (en) 1989-03-15
PH22691A (en) 1988-11-14
US4826876A (en) 1989-05-02
US4910305A (en) 1990-03-20
EP0188351A2 (en) 1986-07-23
ES551005A0 (es) 1987-11-01
PT81844A (en) 1986-02-01
NZ214843A (en) 1989-02-24
IE58867B1 (en) 1993-11-17
JO1439B1 (en) 1988-03-10
FI860229A7 (fi) 1986-07-19
HUT40401A (en) 1986-12-28
EP0188351B1 (en) 1991-03-13
ZA86319B (en) 1986-08-27
DE3678000D1 (de) 1991-04-18
CA1319148C (en) 1993-06-15
HU194807B (en) 1988-03-28
IL77605A (en) 1990-02-09
FI860229A0 (fi) 1986-01-17

Similar Documents

Publication Publication Date Title
DK164592C (da) Thyroninanaloge forbindelser, fremgangsmaader til fremstilling af disse samt farmaceutiske praeparater indeholdende dem
FI893632A0 (fi) Foereningar.
DK159308C (da) 4-aminoquinolinderivater, farmaceutisk middel der indeholder disse samt anvendelse af disse til fremstilling af et laegemiddel
OA06421A (fr) Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides.
DK102892A (da) Purin-derivater, farmaceutisk praeparat omfattende forbindelserne samt forbindelser til brug som mellemprodukter
DE3688087D1 (de) Cephemverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.
DK454685D0 (da) Pyrazolo(3,4-b)-pyridinamider
HUT42102A (en) Process for preparing peptides with pharmaceutical activity
DK16186A (da) Piperazin-1-yl-ergolinderivater, fremgangsmaade til fremstilling heraf og praeparater indeholdende disse forbindelser
ES557149A0 (es) Un procedimiento para la preparacion de derivados peptidicos de histidinilprolinamida.
FR2593180B1 (fr) Derives d'acylaminomethyl-1 imidazo (1,2-a)quinoleines, leur preparation et leur application en therapeutique
SE8506094D0 (sv) New antibacterial agents and intermediates therefor
DK282786D0 (da) Ergolinderivater, fremgangsmaade til fremstilling deraf og forbindelser til anvendelse som mellemprodukter ved fremgangsmaaden samtfarmaceutiske praeparater

Legal Events

Date Code Title Description
PUP Patent expired